Org 214007-0: A Novel Non-Steroidal Selective Glucocorticoid Receptor Modulator with Full Anti-Inflammatory Properties and Improved Therapeutic Index

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  van Lierop, Marie José C ^a   Alkema, Wynand ^a   Laskewitz, Anke J ^b   Dijkema, Rein ^a   van der Maaden, Hans M ^a   Smit, Martin J ^a   Plate, Ralf ^a   Conti, Paolo G M ^a   Jans, Christan G J M ^a   Timmers, C Marco ^a   van Boeckel, Constant A A ^a   Lusher, Scott J ^a   McGuire, Ross ^a   van Schaik, Rene C ^a   de Vlieg, Jacob ^a   Smeets, Ruben L ^a   Hofstra, Claudia L ^a   Boots, Annemieke M H ^b   van Duin, Marcel ^a   Ingelse, Benno A ^a   Schoonen, Willem G E J ^a   Grefhorst, Aldo ^b   van Dijk, Theo H ^b   Kuipers, Folkert ^b   Dokter, Wim H A ^a   more..

^a MSD   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; COLLAGEN; GLUCOCORTICOID RECEPTOR; GLUCOSE; GLYCOGEN; INTERLEUKIN 2; N (8 CYANO 1,2,3,4,10,14B HEXAHYDRO 10 METHYLDIBENZO[C,F]PYRIDO[1,2 A]AZEPIN 2 YL) 4 METHYL 1,2,3 THIADIAZOLE 5 CARBOXAMIDE; ORG 214007 0; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALPHA HELIX; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG BINDING SITE; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; FEMALE; GENE EXPRESSION PROFILING; GENE INDUCTION; GENE REPRESSION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IN VIVO STUDY; INFLAMMATION; LIVER; MALE; MOUSE; NONHUMAN; RECEPTOR OCCUPANCY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; BLOOD GLUCOSE; DIBENZAZEPINES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; KINETICS; LIVER; MALE; MICE; MOLECULAR DOCKING SIMULATION; PREDNISOLONE; PROTEIN BINDING; RECEPTORS, GLUCOCORTICOID; THIADIAZOLES;

MUS;

EID: 84869055083     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048385     Document Type: Article

References (54)

1. Schäcke H, Döcke WD, Asadullah K, (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 96: 23-43.
2. van Raalte DH, Ouwens DM, Diamant M, (2009) Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest. 39: 81-93.
3. Beck IM, Vanden Berghe W, Vermeulen L, Yamamoto KR, Haegeman G, et al. (2009) Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases Endocr Rev. 30: 830-882.
4. De Bosscher K, Haegeman G, (2009) Minireview: Latest perspectives on antiinflammatory actions of glucocorticoids. Mol Endocrinol. 23: 281-291.
5. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, et al. (1998) DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93: 531-541.
6. Schäcke H, Schottelius A, Döcke WD, Strehlke P, Jaroch S, et al. (2004) Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A. 101: 227-232.
7. Frijters R, Fleuren W, Toonen EJ, Tuckermann JP, Reichardt HM, et al. (2010) Prednisolone-induced differential gene expression in mouse liver carrying wild type or a dimerization-defective glucocorticoid receptor. BMC Genomics 11: 359-372.
8. Ronacher K, Hadley K, Avenant C, Stubsrud E, Simons SS Jr, et al. (2009) Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of co-factor interaction. Mol Cell Endocrinol. 299: 219-231.
9. Kumar R, Thompson EB, (2005) Gene regulation by the glucocorticoid receptor: structure:function relationship. J Steroid Biochem Mol Biol. 94: 383-394.
10. Belvisi MG, Wicks SL, Battram CH, Bottoms SE, Redford JE, et al. (2001) Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J. Immunol. 166: 1975-1982.
11. De Bosscher K, Haegeman G, Elewaut D, (2010) Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol. 10: 497-504.
12. Miner JN, Ardecky B, Benbatoul K, Griffiths K, Larson CJ, et al. (2007) Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci U S A. 104: 19244-19249.
13. Clark AR, (2007) Anti-inflammatory functions of glucocorticoid-induced genes. Mol. Cell. Endocrinol. 275: 79-97.
14. Newton R, Holden NS, (2007) Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol. 72: 799-809.
15. Surjit M, Ganti KP, Mukherji A, Ye T, Hua G, et al. (2011) Widespread negative response elements mediate direct repression by agonist- liganded glucocorticoid receptor. Cell 145: 224-241.
16. Baschant U, Frappart L, Rauchhaus U, Bruns L, Reichardt HM, et al. (2011) Glucocorticoid therapy of antigen-induced arthritis depends on the dimerized glucocorticoid receptor in T cells. Proc Natl Acad Sci U S A. 108: 19317-19322.
17. Liberman AC, Druker J, Perone MJ, Arzt E, (2007) Glucocorticoids in the regulation of transcription factors that control cytokine synthesis. Cytokine Growth Factor Rev. 1-2: 45-56.
18. Biggadike K, Bledsoe RK, Hassell AM, Kirk BE, McLay IM, et al. (2008) X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J Med Chem. 51: 3349-3352.
19. Biggadike K, Bledsoe RK, Coe DM, Cooper TW, House D, et al. (2009) Design and x-ray crystal structures of high-potency nonsteroidal glucocorticoid agonists exploiting a novel binding site on the receptor. Proc Natl Acad Sci U S A. 106: 18114-18119.
20. Kauppi B, Jakob C, Färnegårdh M, Yang J, Ahola H, et al. (2003) The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem. 278: 22748-22754.
21. De Bosscher K, Beck IM, Haegeman G, (2010) Classic glucocorticoids versus non-steroidal glucocorticoid receptor modulators: survival of the fittest regulator of the immune system? Brain Behav Immun. 24: 1035-1042.
22. Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, et al. (2002) Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110: 93-105.
23. Kroe RR, Baker MA, Brown MP, Farrow NA, Gautschi E, et al. (2007) Agonist versus antagonist induce distinct thermodynamic modes of co-factor binding to the glucocorticoid receptor. Biophys Chem. 128: 156-164.
24. Sun Y, Tao YG, Kagan BL, He Y, Simons SS Jr, (2008) Modulation of transcription parameters in glucocorticoid receptor-mediated repression. Mol Cell Endocrinol. 295: 59-69.
25. Plate R, Jans CGLM (2007) Non-steroidal compounds useful as glucocorticoid receptor modulators. WO 2007/025938.
26. Lusher SJ, Conti P, Dokter W, Hermkens PH, de Vlieg J (2011) Drug Design Approaches to Manipulate the Agonist - Antagonist Equilibrium in Steroid Receptors. In: Hassan Abduljabbar editor. Steroids - Basic Science, Croatia, InTech 221-234.
27. Kunkel EJ, Plavec I, Nguyen D, Melrose J, Rosler ES, et al. (2004) Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models. Assay Drug Dev Technol. 2: 0431-441.
28. Berg EL, Kunkel EJ, Hytopoulos E, Plavec I, (2006) Characterization of compound mechanisms and secondary activities by BioMAP analysis. J Pharmacol Toxicol Methods. 53: 67-74.
29. Lucibello FC, Slater EP, Jooss KU, Beato M, Müller R, (1990) Mutual transrepression of Fos and the glucocorticoid receptor: involvement of a functional domain in Fos which is absent in FosB. EMBO J. 9: 2827-2834.
30. Rauch A, Seitz S, Baschant U, Schilling AF, Illing A, et al. (2010) Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 11: 517-531.
31. De Bosscher K, Vanden Berghe W, Beck IM, Van Molle W, Hennuyer N, et al. (2005) A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci U S A. 102: 15827-15832.
32. Robertson S, Allie-Reid F, Vanden Berghe W, Visser K, Binder A, et al. (2010) Abrogation of glucocorticoid receptor dimerization correlates with dissociated glucocorticoid behavior of compound a. Biol Chem. 285: 8061-8075.
33. Wu J, Li Y, Dietz J, Lala DS, (2004) Repression of p65 Transcriptional Activation by the Glucocorticoid Receptor in the Absence of Receptor-Coactivator Interactions. Mol. Endocrinol. 18: 53-62.
34. Ehrchen JM, Sunderkötter C, Foell D, Vogl T, Roth J, (2009) The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 86: 557-566.
35. Henningsen J, Pedersen BK, Kratchmarova I, (2011) Quantitative analysis of the secretion of the MCP family of chemokines by muscle cells. Mol Biosyst. 7: 311-321.
36. Toonen EJM, Fleuren WW, Nässander U, van Lierop MJ, Bauerschmidt S, et al. (2011) Prednisolone induced changes in gene expression profiles in healthy volunteers. Pharmacogenomics 12: 985-998.
37. Waddell DS, Baehr LM, van den Brandt J, Johnsen SA, Reichardt HM, et al. (2008) The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am J Physiol Endocrinol Metab. 295: E785-797.
38. So AY, Bernal TU, Pillsbury ML, Yamamoto KR, Feldman BJ, (2009) Glucocorticoid regulation of the circadian clock modulates glucose homeostasis. Proc Natl Acad Sci U S A 106: 17582-17587.
39. ng BV, Weinstein DS, Doweyko LM, Gong H, Vaccaro W, et al. (2010) Dimethyl-diphenyl-propanamide Derivatives As Nonsteroidal Dissociated Glucocorticoid Receptor Agonists. J Med Chem. 53: 8241-8251.
40. Riether D, Harcken C, Razavi H, Kuzmich D, Gilmore T, et al. (2010) Nonsteroidal dissociated glucocorticoid agonists containing azaindoles as steroid A-ring mimetics. J Med Chem. 53: 6681-6698.
41. Laskewitz AJ, van Dijk TH, Grefhorst A, van Lierop MJ, Schreurs M, et al. (2012) Chronic Prednisolone Treatment Aggravates Hyperglycemia in Mice Fed a High-Fat Diet but Does Not Worsen Dietary Fat-Induced Insulin Resistance. Endocrinology 153: 3713-3723.
42. Hellerstein MK, Neese RA, Linfoot P, Christiansen M, Turner S, et al. (1997) Hepatic gluconeogenic fluxes and glycogen turnover during fasting in humans. A stable isotope study. J Clin Invest. 100: 1305-1319.
43. van Dijk TH, Boer TS, Havinga R, Stellaard F, Kuipers F, et al. (2003) Quantification of hepatic carbohydrate metabolism in conscious mice using serial blood and urine spots. Anal Biochem. 322: 1-13.
44. van Raalte DH, Nofrate V, Bunck MC, van Iersel T, Elassaiss Schaap J, et al. (2010) Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men. Eur J Endocrinol. 162: 729-735.
45. Nielsen MF, Caumo A, Chandramouli V, Schumann WC, Cobelli C, et al. (2004) Impaired basal glucose effectiveness but unaltered fasting glucose release and gluconeogenesis during short-term hypercortisolemia in healthy subjects. Am J Physiol Endocrinol Metab. 286: E102-110.
46. Wajngot A, Khan A, Giacca A, Vranic M, Efendic S, (1990) Dexamethasone increases glucose cycling, but not glucose production, in healthy subjects. Am J Physiol. 259: E626-632.
47. Laskewitz AJ, van Dijk TH, Bloks VW, Reijngoud DJ, van Lierop MJ, et al. (2010) Chronic prednisolone treatment reduces hepatic insulin sensitivity while perturbing the fed-to-fasting transition in mice. Endocrinology 151: 2171-2178.
48. Nabuurs SB, Wagener M, de Vlieg J, (2007) A flexible approach to induced fit docking. J. Med. Chem. 50: 6507-6518.
49. an RA, Cox JJ, Beischlag TV, Burbach JP, (1993) A composite hormone response element mediates the transactivation of the rat oxytocin gene by different classes of nuclear hormone receptors. Mol Endocrinol. 7: 47-57.
50. de Groot DM, Vogel G, Dulos J, Teeuwen L, Stebbins K, et al. (2009) Therapeutic antibody targeting of CD97 in experimental arthritis: the role of antigen expression, shedding, and internalization on the pharmacokinetics of anti-CD97 monoclonal antibody 1B2. J Immunol. 183: 4127-4134.
51. Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, et al. (1999) IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J. Immunol. 163: 5049-5055.
52. van Dijk TH, van der Sluijs FH, Wiegman CH, Baller JF, Gustafson LA, et al. (2001) Acute inhibition of hepatic glucose-6-phosphatase does not affect gluconeogenesis but directs gluconeogenic flux toward glycogen in fasted rats. A pharmacological study with the chlorogenic acid derivative S4048. J Biol Chem. 276: 25727-25735.
53. Bandsma RH, Grefhorst A, van Dijk TH, van der Sluijs FH, Hammer A, et al. (2004) Enhanced glucose cycling and suppressed de novo synthesis of glucose-6-phosphate result in a net unchanged hepatic glucose output in ob/ob mice. Diabetologia 47: 2022-2031.
54. Paakinaho V, Makkonen H, Jääskeläinen T, Palvimo JJ, (2010) Glucocorticoid receptor activates poised FKBP51 locus through long-distance interactions. Mol Endocrinol. 24: 511-525.